Key result
Active metastatic cancer is linked to ~4.8-fold higher 1-year mortality after ischaemic stroke.
Why the study?
Cancer is frequent in ischaemic stroke patients, prompting an examination of its association with 1-year outcome and its relation to patient characteristics, stroke management, or underlying malignancy.
Is cancer status (stratified by remission, active nonmetastatic, and active metastatic disease) associated with 1-year all-cause mortality and functional outcome in patients with acute ischaemic stroke?
Cohort (n=1,351)
Assessors not formally blinded to cancer status, but unaware of the specific hypothesis under study
Yes
Is cancer status (stratified by remission, active nonmetastatic, and active metastatic disease) associated with 1-year all-cause mortality and functional outcome in patients with acute ischaemic stroke?
Post-ischaemic stroke 1-year mortality is strongly graded by cancer activity and metastatic burden rather than a history of cancer in remission, accruing mainly after the acute 30-day phase and not explained by differences in acute revascularisation access.
Answers are grounded in this paper and cite their sources.
Active metastatic cancer signals high post-stroke mortality risk; extends prior observations but leaves open whether targeted interventions improve survival.
Introduction Cancer is frequent in ischaemic stroke patients. We examined its association with 1-year outcome, and whether it relates to patient characteristics, stroke management or underlying malignancy. Patients and methods Patients were retrieved from the population-based Dijon Stroke Registry, France (2017-2022), and categorised as having no cancer, cancer in remission, active nonmetastatic or metastatic cancer. Primary outcome was 1-year all-cause mortality (Cox regression and day-30 landmark analysis). Secondary outcome was 1-year functional outcome (mRS score, ordinal logistic regression over the full scale and among survivors). Access to acute revascularisation therapy was compared across cancer categories. Results Among 1351 patients, 262 (19.4%) had a history of cancer: 10.1% in remission, 5.3% active nonmetastatic and 3.9% active metastatic. One-year mortality rose across groups, from 27.2% without cancer to 29.2%, 41.7% and 64.2%. After adjustment, active nonmetastatic (hazard ratio [HR] 1.58; 95% CI, 1.07–2.32) and metastatic cancer (HR 4.80; 95% CI, 3.30–6.97) were associated with mortality. This strengthened in the landmark analysis. Metastatic cancer was associated with worse functional outcome overall (odds ratio [OR] 9.04; 95% CI, 4.64–17.6). Among the 19 patients with active metastatic cancer who survived to 1 year, no excess disability was detectable (OR 0.71; 95% CI, 0.32–1.60). Revascularisation therapy did not differ significantly by cancer status. Discussion The prognostic burden of cancer was graded by disease activity and metastatic extent, and accrued beyond the acute phase, unrelated to acute care. The functional impact of metastatic cancer was largely explained by mortality. Conclusions Prognostic assessment stratified by cancer activity and burden is warranted after ischaemic stroke.
No takes yet. Share an insight, caveat, or question.
Kassir et al. (2026) conducted a cohort in Acute ischaemic stroke (n=1,351). Active metastatic cancer vs. No cancer (reference group; also compared with cancer in remission and active nonmetastatic cancer) was evaluated on 1-year all-cause mortality (HR 4.80, 95% CI 3.30-6.97, p=<0.001). Active metastatic cancer was associated with higher 1-year all-cause mortality after ischaemic stroke compared with no cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: